tbuckley/cabot-search huggingface dataset:
Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women
Authors: Chantale Dumoulin, Mélanie Morin, Coraline Danieli, Licia Cacciari, Marie-Hélène Mayrand, Michel Tousignant, Michal Abrahamowicz
Journal: JAMA Internal Medicine (2020)

Urinary incontinence is one of the most prevalent health concerns experienced by older women (aged ≥60 years). Individual pelvic floor muscle training (PFMT) is the recommended first-line treatment for stress or mixed urinary incontinence in women, but human and financial resources limit its delivery. Whether group-based PFMT performs as well as individual PFMT in this population remains unclear.To assess the efficacy of group-based PFMT relative to individual PFMT for urinary incontinence in older women.The Group Rehabilitation or Individual Physiotherapy (GROUP) study is a single-blind, randomized, noninferiority trial conducted in 2 Canadian research centers, from July 1, 2012, to June 2, 2018. A total of 362 community-dwelling women aged 60 years or older with symptoms of stress or mixed urinary incontinence were enrolled.After an individual session conducted to learn how to contract pelvic floor muscles, participants completed 12-week PFMT as part of a group of 8 women (n = 178) or in individual sessions (n = 184).The primary outcome measure was the percentage reduction in urinary incontinence episodes at 1 year, as reported in a 7-day bladder diary and relative to pretreatment baseline. Secondary outcomes included lower urinary tract-related signs, symptoms, and quality of life immediately following treatment and at 1 year. Per-protocol analysis was used.Among 362 women who were randomized (mean [SD] age, 67.9 [5.8] years), 319 women (88%) completed the 1-year follow-up and were included in the per-protocol analysis. Median percentage reduction in urinary incontinence episodes was 70% (95% CI, 44%-89%) in individual PFMT compared with 74% (95% CI, 46%-86%) in group-based PFMT. The upper boundary of the 95% CI for the difference in the percentage reduction in urinary incontinence episodes at 1 year was lower than the prespecified margin for noninferiority of 10% (difference, 4%; 95% CI, -10% to 7%; P = .58), confirming noninferiority. Individual PFMT and group-based PFMT had similar effectiveness for all secondary outcomes at 1 year. Adverse events were minor and uncommon.Results of the GROUP study suggest that group-based PFMT is not inferior to the recommended individual PFMT for the treatment of stress and mixed urinary incontinence in older women. Widespread use in clinical practice may help increase continence-care affordability and treatment availability.ClinicalTrials.gov Identifier: NCT02039830.
Abstract 15374: Pulmonary Hypertension and Pulmonary Vascular Disease in Patients With a Subaortic Right Ventricle: Prevalence, Impact and Management
Authors: Alexander Van De Bruaene, Norihisa Toh, Edward J Hickey, Lee Benson, Eric Horlick, William G Williams, S. Lucy Roche
Journal: Circulation (2018)

Introduction: Pulmonary hypertension (PH) in patients with a subaortic right ventricle in a biventricular circulation (2V-RV) is a concern. Since 2012, we routinely refer 2V-RV patients >40 years a...
Engineering Multi‐Cellular Spheroids for Tissue Engineering and Regenerative Medicine
Authors: Se‐jeong Kim, Eun Mi Kim, Masaya Yamamoto, Hansoo Park, Heungsoo Shin
Journal: Advanced Healthcare Materials (2020)

Abstract Multi‐cellular spheroids are formed as a 3D structure with dense cell–cell/cell–extracellular matrix interactions, and thus, have been widely utilized as implantable therapeutics and various ex vivo tissue models in tissue engineering. In principle, spheroid culture methods maximize cell–cell cohesion and induce spontaneous cellular assembly while minimizing cellular interactions with substrates by using physical forces such as gravitational or centrifugal forces, protein‐repellant biomaterials, and micro‐structured surfaces. In addition, biofunctional materials including magnetic nanoparticles, polymer microspheres, and nanofiber particles are combined with cells to harvest composite spheroids, to accelerate spheroid formation, to increase the mechanical properties and viability of spheroids, and to direct differentiation of stem cells into desirable cell types. Biocompatible hydrogels are developed to produce microgels for the fabrication of size‐controlled spheroids with high efficiency. Recently, spheroids have been further engineered to fabricate structurally and functionally reliable in vitro artificial 3D tissues of the desired shape with enhanced specific biological functions. This paper reviews the overall characteristics of spheroids and general/advanced spheroid culture techniques. Significant roles of functional biomaterials in advanced spheroid engineering with emphasis on the use of spheroids in the reconstruction of artificial 3D tissue for tissue engineering are also thoroughly discussed.
FRI0100 Prednisone (pred), azathioprine (aza) and cyclosporin a (csa) combination is effective for membranous lupus nephritis (mnl)
Authors: EK Li, LS Tam, CC Szeto, FM Lai, SM Wong, CB Leung, KC Wong, SF Lui
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> <h3>Methods</h3> 10 consecutive female patients with mean age 35 ¡Ó 10 years and the mean disease duration prior to the onset of the index episode of nephritis was 86 ¡Ó 85 months with pure MLN were treated with prednisolone, AZA and CSA for at least 12 months. CSA was tapered in stable patients by 18–24 months. All patients were followed for 3 years. <h3>Results</h3> At 1 year, 4 patients achieved complete response as defined as serum albumin over 35 g/L, urinary protein less than 0.3 g/day and serum creatinine less than 30% above the baseline value and 3 achieved partial response. One patient developed agranulocytosis and alopecia totalis, another patient withdrawn at 6 months because of inefficacy, and one patient had no response at 1 year. For the responders, serum albumin increased from 22.8 ¡Ó 5.1 to 34.4 ¡Ó 2.7 mg/l, accompanied by reduction in urine protein from 5.6 ¡Ó 3.2 to 0.8 ¡Ó 0.8 g/day, while serum creatinine remained unchanged. Significant increase in serum albumin and sustained reduction in urine protein were noted from 3 months onward. Creatinine clearance showed significant improvement by the end of 1 year. Serum C3 normalised in 3 out of 6 patients, whereas anti – ds DNA antibodies became negative in 5 out of 6 patients. The mean prednisone dose reduced from 26.8 ¡Ó 5.5 to 5.7 ¡Ó 1.9 mg/day, the mean dose of CSA also reduced from 235.7 ¡Ó 24.4 to 132.1 ¡Ó 49.4 mg/day at the end of 1 year. Side effects included hypertension requiring additional anti-hypertensives in 4 patients, minor infections in 2 patients and leucopenia in 1 patient. CSA was tapered by the end of second year in 4 patients. At 3 years, 6 patients had sustained response, 2 patients developed renal relapse at 18 and 20 months. One patient reached end stage renal failure at 27 months. <h3>Conclusion</h3> Combination therapy using prednisolone, AZA and CSA is well tolerated and is efficacious in the management of MLN, and may prevent relapse in patients after stopping CSA.
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
Authors: Sabela Bobillo, Erel Joffe, Jessica A. Lavery, David Sermer, Paola Ghione, Ariela Noy, Philip C. Caron, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Alison Moskowitz, Collette N. Owens, M. Lia Palomba, Connie L. Batlevi, David Straus, Gottfried von Keudell, Andrew D. Zelenetz, Joachim Yahalom, Ahmet Dogan, Venkatraman E. Seshan, Anas Younes
Journal: Blood (2020)
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study
Authors: Jean-Marie Michot, Reda Bouabdallah, Umberto Vitolo, Jeanette K Doorduijn, Gilles Salles, Annalisa Chiappella, Pier Luigi Zinzani, Fontanet Bijou, Marie José Kersten, Rafael Sarmiento, Silvia Mosulen, Cristina Mendez, Shailaja Uttamsingh, Michael Pourdehnad, Kristen Hege, Tianlei Chen, Christian Klein, Patrick R Hagner, Zariana Nikolova, Vincent Ribrag
Journal: The Lancet Haematology (2020)
AB0016 ASSOCIATION OF PTPN22 GENETIC VARIANTS WITH DISEASE SUSCEPTIBILITY AND CLINICAL VARIABLES IN PRIMARY SJÖGREN SYNDROME
Authors: P. A. Menchaca Tapia, E. Oregón Romero, D. C. Salazar Camarena, M. Marin Rosales, J. F. Muñoz Valle, C. A. Palafox Sánchez
Journal: Annals of the Rheumatic Diseases (2020)

Background: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by dysfunction of exocrine glands secondary to lymphocytic infiltration. Lymphoid tyrosine phosphatase (LYP) regulates T and B lymphocyte activation. PTPN22 gene encodes LYP; multiple polymorphic variants have been described as genetic risk factor of autoimmune diseases. Objectives: The aim was to analyze the PTPN22 rs2488457G&gt;C, rs33996649G&gt;A, and rs2476601C&gt;T genetic variants relationship with the development risk of pSS in the western Mexico population. Methods: One hundred and eighty healthy subjects (HS) and 150 pSS patients, classified according to EULAR 2016 criteria, were included. The genetic variants and mRNA expression were determined through PCR-RFLP and qPCR assays. Results: The frequency of heterozygote rs33996649GA genotype was higher in pSS patients than HS [OR=3.143 (1–10.234), p=0.046], and also, rs33996649GA genotype was associated with high SSDAI score (p=0.01). The pSS patients showed 44-fold more mRNA expression in comparison with HS (p=0.002), and mRNA expression correlates with SSDAI (r 2 =0.512, p=0.006). Conclusion: The rs33996649G&gt;A genetic variant of the PTPN22 gene is associated with increased development risk of pSS in the western Mexican population. The expression mRNA correlates with disease activity in pSS. References: [1]Brito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Ramos-Casals, M. (2016). Sjögren syndrome. Nature Reviews Disease Primers , 2(July), 1–20. https://doi.org/10.1038/nrdp.2016.47 [2]Stanford, S. M., &amp; Bottini, N. (2014). PTPN22: The archetypal non-HLA autoimmunity gene. Nature Reviews Rheumatology , 10 (10), 602–611.https://doi.org/10.1038/nrrheum.2014.109 [3]Chen, Z., Zhang, H., Xia, B., Wang, P., Jiang, T., Song, M., &amp; Wu, J. (2013). Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis. International Journal of Colorectal Disease , 28 (10), 1351–1358. https://doi.org/10.1007/s00384-013-1671-3 [4]Machado-Contreras, J. R., Muñoz-Valle, J. F., Cruz, A., Salazar-Camarena, D. C., Marín- Rosales, M., &amp; Palafox-Sánchez, C. A. (2016b). Distribution of PTPN22 polymorphismsin SLE from western Mexico: correlation with mRNA expression and disease activity. Clinical and Experimental Medicine , 16 (3), 399–406. https://doi.org/10.1007/s10238-015-0359-0 Disclosure of Interests: None declared
US Mortality Attributable to Congenital Heart Disease Across the Lifespan From 1999 Through 2017 Exposes Persistent Racial/Ethnic Disparities
Authors: Keila N. Lopez, Shaine A. Morris, S. Kristen Sexson Tejtel, Andre Espaillat, Jason L. Salemi
Journal: Circulation (2020)

Background: Congenital heart disease (CHD) accounts for ≈40% of deaths in US children with birth defects. Previous US data from 1999 to 2006 demonstrated an overall decrease in CHD mortality. Our study aimed to assess current trends in US mortality related to CHD from infancy to adulthood over the past 19 years and determine differences by sex and race/ethnicity. Methods: We conducted an analysis of death certificates from 1999 to 2017 to calculate annual CHD mortality by age at death, race/ethnicity, and sex. Population estimates used as denominators in mortality rate calculations for infants were based on National Center for Health Statistics live birth data. Mortality rates in individuals ≥1 year of age used US Census Bureau bridged-race population estimates as denominators. We used joinpoint regression to characterize temporal trends in all-cause mortality, mortality resulting directly attributable to and related to CHD by age, race/ethnicity, and sex. Results: There were 47.7 million deaths with 1 in 814 deaths attributable to CHD (n=58 599). Although all-cause mortality decreased 16.4% across all ages, mortality resulting from CHD declined 39.4% overall. The mean annual decrease in CHD mortality was 2.6%, with the largest decrease for those &gt;65 years of age. The age-adjusted mortality rate decreased from 1.37 to 0.83 per 100 000. Males had higher mortality attributable to CHD than females throughout the study, although both sexes declined at a similar rate (≈40% overall), with a 3% to 4% annual decrease between 1999 and 2009, followed by a slower annual decrease of 1.4% through 2017. Mortality resulting from CHD significantly declined among all races/ethnicities studied, although disparities in mortality persisted for non-Hispanic Blacks versus non-Hispanic Whites (mean annual decrease 2.3% versus 2.6%, respectively; age-adjusted mortality rate 1.67 to 1.05 versus 1.35 to 0.80 per 100 000, respectively). Conclusions: Although overall US mortality attributable to CHD has decreased over the past 19 years, disparities in mortality persist for males in comparison with females and for non-Hispanic Blacks in comparison with non-Hispanic Whites. Determining factors that contribute to these disparities such as access to quality care, timely diagnosis, and maintenance of insurance will be important moving into the next decade.
Gut T cell–independent IgA responses to commensal bacteria require engagement of the TACI receptor on B cells
Authors: E. K. Grasset, A. Chorny, S. Casas-Recasens, C. Gutzeit, G. Bongers, I. Thomsen, L. Chen, Z. He, D. B. Matthews, M. A. Oropallo, P. Veeramreddy, M. Uzzan, A. Mortha, J. Carrillo, B. S. Reis, M. Ramanujam, J. Sintes, G. Magri, P. J. Maglione, C. Cunningham-Rundles, R. J. Bram, J. Faith, S. Mehandru, O. Pabst, A. Cerutti
Journal: Science Immunology (2020)

Signaling by the B cell–activating receptor TACI drives T cell–independent IgA responses to gut commensal bacteria.
Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity
Authors: Themis Alissafi, Lydia Kalafati, Maria Lazari, Anastasia Filia, Ismini Kloukina, Maria Manifava, Jong-Hyung Lim, Vasileia Ismini Alexaki, Nicholas T. Ktistakis, Triantafyllos Doskas, George A. Garinis, Triantafyllos Chavakis, Dimitrios T. Boumpas, Panayotis Verginis
Journal: Cell Metabolism (2020)
Paul Anthony Bramley
Authors: John Williams
Journal: BMJ (2020)

Paul Anthony Bramley was consultant oral surgeon to SW Region Hospital Board (1954-69) and to the Trent Region (1969-1988); professor of dental surgery at the University of Sheffield (1969-88); and dean of the School of Clinical Dentistry (1972-75). He served as a member of the board of faculty and council of the Royal College of Surgeons, and from 1980 to 1983 as dean of the Faculty of Dental Surgery.

He received the prestigious Colyer gold medal from the FDSRCS and was national president of the British Dental Association from 1988 to 1989. He was also an external examiner to the RCS dental professional bodies and many universities at home and abroad. He received honorary degrees from Birmingham, Sheffield, and the Prince of Songkla University in Thailand. He published extensively in professional journals and, with J de B Norman, was the coauthor of a definitive book on the temporomandibular joint (1989).

He was one of few clinicians to serve on the Royal Commission on …
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma
Authors: Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, Han A Li, Samuel A Funt, Chung-Han Lee, David B Solit, Hikmat Al-Ahmadie, Matthew I Milowsky, Arjun V Balar, Eugene Pietzak, Guido Dalbagni, Bernard H Bochner, Irina Ostrovnaya, Dean F Bajorin, Jonathan E Rosenberg, Gopa Iyer
Journal: European Urology (2020)
SAT0060 Osteoarthritis (oa) of the hip: tolerance and efficacy of intra-articular hyaluronic acid (ha)
Authors: O Brocq, V Breuil, G Tran, C Grisot, P Flory, L Euller-Ziegler
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> Intra-articular injection of HA, a visco-supplement, can be an interesting option to treat OA; it has been mostly studied for OA of the knee. We studied the short-term tolerance and efficacy of an intra-articular injection of Hylane G-F 20 (Synvisc) in hip OA. <h3>Methods</h3> We performed an open prospective study in patients with OA of the hip (radiological and/or CT scan criteria: Kellgren radiological score 40 mm and/or Lequesne score &gt;6), without surgery schedule for one year and without any pathology which may contribute to the pain. For each patient, articular amplitudes, VAS and Lequesne score were recorded at day 0,30,60,90,120. The injection of one vial of the drug was realised after radiological verification of the position of the needle by injecting 1/2 cc of a iodic contrast fluid. After <h3>Results</h3> 30 injections were performed in 22 patients (13 F + 9 M), mean aged 54.7 years (37–83). The Kellgren score was: stade 1(2); st 2(11); st 3(9). Two patients with iode allergy were pre-treated by hydroxyzine. The patients received analgesics (all); NSAID (11); MOA (15). <h3>Conclusion</h3> Hylane G-F20 injection in the hip joint appeared to be well tolerated. It may have a special interest in patients &lt;60 years old suffering from hip OA, notably for delaying surgery.
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study
Authors: Kasper Iversen, Henning Bundgaard, Rasmus B Hasselbalch, Jonas H Kristensen, Pernille B Nielsen, Mia Pries-Heje, Andreas D Knudsen, Casper E Christensen, Kamille Fogh, Jakob B Norsk, Ove Andersen, Thea K Fischer, Claus Antonio Juul Jensen, Margit Larsen, Christian Torp-Pedersen, Jørgen Rungby, Sisse B Ditlev, Ida Hageman, Rasmus Møgelvang, Christoffer E Hother, Mikkel Gybel-Brask, Erik Sørensen, Lene Harritshøj, Fredrik Folke, Curt Sten, Thomas Benfield, Susanne Dam Nielsen, Henrik Ullum
Journal: The Lancet Infectious Diseases (2020)

Health-care workers are thought to be highly exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to investigate the prevalence of antibodies against SARS-CoV-2 in health-care workers and the proportion of seroconverted health-care workers with previous symptoms of COVID-19.In this observational cohort study, screening was offered to health-care workers in the Capital Region of Denmark, including medical, nursing, and other students who were associated with hospitals in the region. Screening included point-of-care tests for IgM and IgG antibodies against SARS-CoV-2. Test results and participant characteristics were recorded. Results were compared with findings in blood donors in the Capital Region in the study period.Between April 15 and April 23, 2020, we screened 29 295 health-care workers, of whom 28 792 (98·28%) provided their test results. We identified 1163 (4·04% [95% CI 3·82-4·27]) seropositive health-care workers. Seroprevalence was higher in health-care workers than in blood donors (142 [3·04%] of 4672; risk ratio [RR] 1·33 [95% CI 1·12-1·58]; p<0·001). Seroprevalence was higher in male health-care workers (331 [5·45%] of 6077) than in female health-care workers (832 [3·66%] of 22 715; RR 1·49 [1·31-1·68]; p<0·001). Frontline health-care workers working in hospitals had a significantly higher seroprevalence (779 [4·55%] of 16 356) than health-care workers in other settings (384 [3·29%] of 11 657; RR 1·38 [1·22-1·56]; p<0·001). Health-care workers working on dedicated COVID-19 wards (95 [7·19%] of 1321) had a significantly higher seroprevalence than other frontline health-care workers working in hospitals (696 [4·35%] of 15 983; RR 1·65 [1·34-2·03]; p<0·001). 622 [53·5%] of 1163 seropositive participants reported symptoms attributable to SARS-CoV-2. Loss of taste or smell was the symptom that was most strongly associated with seropositivity (377 [32·39%] of 1164 participants with this symptom were seropositive vs 786 [2·84%] of 27 628 without this symptom; RR 11·38 [10·22-12·68]). The study is registered at ClinicalTrials.gov, NCT04346186.The prevalence of health-care workers with antibodies against SARS-CoV-2 was low but higher than in blood donors. The risk of SARS-CoV-2 infection in health-care workers was related to exposure to infected patients. More than half of seropositive health-care workers reported symptoms attributable to COVID-19.Lundbeck Foundation.
High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening
Authors: Candice Clarke, Maria Prendecki, Amrita Dhutia, Mahrukh A. Ali, Hira Sajjad, Oshini Shivakumar, Liz Lightstone, Peter Kelleher, Matthew C. Pickering, David Thomas, Rawya Charif, Megan Griffith, Stephen P. McAdoo, Michelle Willicombe
Journal: Journal of the American Society of Nephrology (2020)

Strategies to minimize the risk of transmission and acquisition of COVID-19 infection in patients with ESKD receiving in-center hemodialysis have been rapidly implemented across the globe. Despite these interventions, confirmed COVID-19 infection rates have been high in the United Kingdom. Prevalence of asymptomatic disease in an adult hemodialysis population has not been reported. Also, to our knowledge, the development of humoral response to SARS-CoV-2 has not been previously reported in this population. Although serologic testing does not provide information on the infectivity of patients, seroprevalence studies may enable investigation of exposure within dialysis units and hence, assessment of current screening strategies.To investigate the seroprevalence of SARS-CoV-2 antibodies in a hemodialysis population, we used the Abbott IgG assay with the Architect system to test serum samples from 356 patients receiving in-center hemodialysis for SARS-CoV-2 antibodies.Of 356 patients, 121 had been symptomatic when screened before a dialysis session and received an RT-PCR test; 79 (22.2% of the total study population) tested positive for COVID-19. Serologic testing of all 356 patients found 129 (36.2%) who tested positive for SARS-CoV-2 antibodies. Only two patients with PCR-confirmed infection did not seroconvert. Of the 129 patients with SARS-CoV-2 antibodies, 52 (40.3%) had asymptomatic disease or undetected disease by PCR testing alone.We found a high seroprevalence of SARS-CoV-2 antibodies in patients receiving in-center hemodialysis. Serologic evidence of previous infection in asymptomatic or PCR-negative patients suggests that current diagnostic screening strategies may be limited in their ability to detect acute infection.
The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis
Authors: Richard L. Amdur, Rohan Paul, Elizabeth D. Barrows, Danielle Kincaid, Jagadeesan Muralidharan, Ehsan Nobakht, Patricia Centron-Vinales, Muhammad Siddiqi, Samir S. Patel, Dominic S. Raj
Journal: Kidney International (2020)
High-fat food biases hypothalamic and mesolimbic expression of consummatory drives
Authors: Christopher M. Mazzone, Jing Liang-Guallpa, Chia Li, Nora S. Wolcott, Montana H. Boone, Morgan Southern, Nicholas P. Kobzar, Isabel de Araujo Salgado, Deepa M. Reddy, Fangmiao Sun, Yajun Zhang, Yulong Li, Guohong Cui, Michael J. Krashes
Journal: Nature Neuroscience (2020)